TORICARD-5 Nebivolol 5mg Tablet 1's

No data are available on overdosage with Nebivolol.
Symptoms: Symptoms of overdosage with betablockers are: bradycardia, hypotension, bronchospasm and acute cardiac insufficiency.
Treatment: In case of overdosage or hypersensitivity, the patients should be kept under close supervision and be treated in an intensive care ward. Blood glucose levels should be checked. Absorption of any drug residues still present in the gastrointestinal tract can be prevented by gastric lavage and the administration of activated charcoal and a laxative. Artificial respiration may be required. Bradycardia or extensive vagal reactions should be treated with plasma/plasma substitutes and, if necessary, catecholamines. The beta-blocking effect can be counteracted by slow intravenous administration of isoprenaline hydrochloride, starting with a dose of approximately 5 μg/minute, or dobutamine, starting with a dose of 2.55 μg/minute until the required effect has been obtained. In refractory cases isoprenaline can be combined with dopamine. If this does not produce the desired effect either, intravenous administration of glucagon 500-100 μg/kg i.v. may be considered. If required, the injection should be repeated within in one hour, to be followed if required by an i.v. infusion of glucagon 70 μg/kg/h. In extreme cases of treatment-resistant bradycardia, a pacemaker maybe inserted.

 

 

Use in Pregnancy: Nebivolol has pharmacological effects that may cause harmful effects on pregnancy and/or the fetus/newborn. In general, beta-receptor blockers reduce placental perfusion, which has been associated with growth retardation, intrauterine death, abortion or early labour. Adverse effects (e.g. hypoglycemia and bradycardia) may occur in the fetus and newborn infant. If treatment with beta-adrenoceptor blockers is necessary, beta-selective adrenoceptor blockers are preferable. Nebivolol should not be used during pregnancy unless clearly necessary. If treatment with nebivolol is considered necessary, the uteroplacental blood flow and fetal growth should be monitored. In case harmful effects on pregnancy of the fetus alternative treatment should be considered. The newborn infant must be closely monitored. Symptoms of hypoglycemia and bradycardia are generally to be expected within first 3 days.
Use in Lactation: Animal studies have shown that nebivolol is excreted in breast milk. It is not known whether this drug is excreted in human milk. Most beta-blockers, particularly lipophilic compounds like nebivolol and its active metabolites pass into breast milk although to a variable content. Therefore, breast feeding is not recommended during administration of nebivolol.

 

Store at temperatures not exceeding 30°C. Protect from light.

Pharmacology: Pharmacodynamics: Nebivolol is a racemeate of two enantiomers, SRRR-nebivolol (or d-nebivolol) and RSSS-nebivolol (or l-nebivolol). It combines two pharmacological activities: It is a competitive and selective beta-receptor antagonist; this effect is attributed to the SRRR-enantiomer (d-enantiomer); It has mild vasodilating properties due to an interaction with L-arginine/nitric oxide pathway.
Single and repeated doses of nebivolol reduce heart rate and blood pressure at rest and during exercise, both in normotensive subjects and in hypertensive patients. The antihypertensive effect is maintained during chronic treatment. At therapeutic doses, nebivolol is devoid of alpha-adrenergic antagonism.
During acute and chronic treatment with nebivolol in hypertensive patients systemic vascular resistance is decreased. Despite heart rate reduction, reduction in cardiac output during rest and exercise may be limited due to an increase in stroke volume. The clinical relevance of these haemodynamic differences as compared to other beta 1 receptor antagonists has not been fully established.
In hypertensive patients, nebivolol increases the NO-mediated vascular response to acetylcholine (Ach) which is reduced in patients with endothelial dysfunction.
In a mortality-morbidity, placebo-controlled trial performed in 2128 patients >70 years (median age 75.2 years) with stable chronic heart failure with or without impaired left ventricular ejection fraction (mean LVEF: 36 ± 12.3%, with the following distribution: LVEF less than 35% in 56% of patients, LVEF between 35% and 45% in 25% of patients and LVEF greater that 45% in 19% of patients) followed for a mean time of 20 months, nebivolol, on top of standard therapy, significantly prolonged the time to occurrence of deaths or hospitalizations for cardiovascular reasons (primary end-point for efficacy) with a relative risk reduction of 14% (absolute reduction: 4.2%). This risk reduction developed after 6 months of treatment and was maintained for all treatment duration (median duration: 18 months). The effect of nebivolol was independent from age, gender, or left ventricular ejection fraction of the population on study. The benefit on all cause mortality did not reach statistical significance in comparison to placebo (absolute reduction: 2.3%).
A decrease in sudden death was observed in nebivolol treated patients (4.1% vs. 6.6%, relative reduction 38%).
In vitro and in vivo experiments in animals showed that nebivolol has no intrinsic sympathicomometic activity.
In vitro and in vivo experiments in animals showed that at pharmacological doses nebivolol has no membrane stabilizing action. In healthy volunteers, nebivolol has no significant effect on maximal exercise capacity or endurance.
Pharmacokinetics: Both nebivolol enantiomers are rapidly absorbed after oral administration. The absorption of nebivolol is not affected by food; nebivolol can be given with or without meals. Nebivolol is extensively metabolized, partly to active hydroxyl-metabolites. Nebivolol is metabolized via alicylic and aromatic hydroxylation, N-dealkylation and glucuronidation; in addition, glucuronides of the hydroxyl-metabolites are formed. The metabolism of nebivolol by aromatic hydroxylation is subject to the CYP2D6 dependent genetic oxidative polymorphism. The oral bioavailability of nebivolol averages 12% in fast metabolizers and is virtually complete in slow metabolizers. At steady state and the same dose level, the peak plasma concentration of unchanged nebivolol is about 23 times higher in poor metabolizers than in extensive metabolizers. When unchanged drug plus active metabolites are considered, the difference in peak plasma concentrations is 1.3 to 1.4 fold. Because of the variation in rate of metabolism, the dose of nebivolol should always be adjusted to the individual requirements of the patient: poor metabolizers therefore may require lower dose.
In fast metabolizers, elimination half-lives of nebivolol enantiomers average 10 hours. In slow metabolizers, there are 3-5 times longer. In fast metabolizers, plasma levels of the RSSS-enantiomer are slightly higher than SRRR-enantiomer. In slow metabolizers, this difference is larger. In fast metabolizers, eliminations half-lives of the hydroxyl metabolites of both enantiomers average 24 hours, and are about twice as long as slow metabolizers.
Steady-state plasma levels in most subjects (fast metabolizers) are reached within 24 hours for nebivolol and within a few days for the hydroxyl-metabolites. Plasma concentrations are dose-proportional between 1 mg and 30 mg. The pharmacokinetics is not affected by age.
In plasma, both nebivolol enantiomers are predominantly bound to albumin. Plasma protein binding is 98.1% for SRRR-nebivolol and 97.9% for RSSS-nebivolol.
One week after administration, 38% of the dose is excreted in the urine and 48% in the feces. Urinary excretion of unchanged nebivolol is less than 0.5% of the dose.